Program
Interleukin-2
Also written as “Recombinant Human Interleukin-2 and Rituximab”, “IL-2 (interleukin 2)” and “Interleukin 2 subcutaneous injection”.
Its studies are mostly in Lymphoma, Non-Hodgkin · Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Melanoma · Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiron | 30 open or running | phase 3since Sep 12, 2002 | Sep 12, 2002 | none ahead |
| Hangzhou Huasai Biomedicine | 22 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Aug 30, 2027phase 1 · NCT07105176 |
| Clinigen | 10 open or running | phase 4since May 10, 2013 | May 10, 2013 | none ahead |
Also a collaborator on its studies: orion-clinical-services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2002First study: phase 3 study in Lymphoma, Non-HodgkinNew to ChironChiron · NCT00045877 · United States
- Sep 12, 2002Phase 2 study in Lymphoma, Non-HodgkinChiron · NCT00045864 · United States
- Jan 6, 2005Phase 2 study in Lymphoma, Non-HodgkinChiron · NCT00100737 · 300 enrolled · United States
- May 10, 2013Clinigen's first study: phase 4 study in MelanomaNew to ClinigenClinigen · NCT01856023 · 29 enrolled · United States
- Jul 22, 2025Hangzhou Huasai Biomedicine's first study: phase 1 study in Advanced Non-Small Cell Lung CancerNew to Hangzhou Huasai BiomedicineHangzhou Huasai Biomedicine · NCT07105176 · 12 planned · China
- Sep 15, 2026Phase 1 study in Advanced NSCLCHangzhou Huasai Biomedicine · NCT07830342 · 24 planned · China
Ahead
- Aug 30, 2027Primary completion: phase 1 study in Advanced Non-Small Cell Lung CancerHangzhou Huasai Biomedicine · NCT07105176
- Oct 2028Primary completion: phase 1 study in Advanced NSCLCHangzhou Huasai Biomedicine · NCT07830342
TargetBeta
“Interleukin-2 receptor agonist”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07830342Advanced NSCLC · China | 1 | Recruiting | Hangzhou Huasai Biomedicine | Oct 2028 | 24 |
| NCT07105176Advanced Non-Small Cell Lung Cancer · China | 1 | Recruiting | Hangzhou Huasai Biomedicine | Aug 30, 2027 | 12 |
| NCT01856023Melanoma · United States | 4 | Terminated | Clinigen | Jul 2015 | 29 |
| NCT00100737Lymphoma, Non-Hodgkin · United States | 2 | Terminated | Chiron | 300 | |
| NCT00045877Lymphoma, Non-Hodgkin · United States | 3 | Completed | Chiron | ||
| NCT00045864Lymphoma, Non-Hodgkin · United States | 2 | Completed | Chiron |
How it is read
Names in the registry
- “Interleukin-2”, 3 entries
- “Recombinant Human Interleukin-2 and Rituximab”, 2 entries
- “IL-2 (interleukin 2)”, 1 entry
- “Interleukin 2 subcutaneous injection”, 1 entry
- “High Dose Interleukin-2”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 3 studies
- Carcinoma, Renal Cell, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Melanoma, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.